When UK quantum computing firm Quantum Motion decided where to build their next laboratory in 2024, they had the world to choose from. They picked Sydney. When Korean industrial giant POSCO wanted to establish their first Critical Minerals R&D Lab, they chose Perth.
What do these global innovators know that you might be missing?
Australia offers one of the world’s most generous R&D support systems, with cash refunds of up to 43.5% on eligible research expenditure. But here’s what catches most international founders off guard: You can’t just set up shop and expect the money to flow. The way you structure your Australian subsidiary of a foreign company from day one determines whether you’ll unlock these substantial benefits or find yourself locked out entirely.
This guide walks you through exactly what you need to know before you commit a single dollar to an Australian expansion.
Australia’s $14.4 Billion Innovation Opportunity
Let’s start with the numbers that matter. The Australian government has committed $14.4 billion in R&D support for 2024-25, that’s roughly £7.5 billion or US$9.3 billion.
More importantly, this isn’t election-year posturing. Major investments like the Medical Research Future Fund were established by previous governments and have survived multiple changes in administration. When you’re planning multi-year R&D investments, that kind of political stability matters.
But the real validation comes from watching where sophisticated companies are actually putting their money. Quantum Motion opened their Australian laboratory in Sydney in September 2024, with their CEO citing “the quality of research and talent in Australia” as the deciding factor. POSCO launched their first Critical Minerals R&D Lab in Perth in June 2025, betting on Australia’s expertise in battery materials and low-carbon steel technologies.
For technology companies, you’re looking at an ecosystem that contributes $167 billion annually to the economy and employs over 860,000 people, making tech Australia’s third-largest industry.
For life sciences companies, Australia consistently ranks in the top five nations globally for biotechnology innovation, with over 2,900 organisations employing approximately 263,693 people. What really matters is the operational environment: world-class medical research infrastructure, efficient regulatory pathways, and a track record of taking discoveries from lab to market.
The financial incentives are the hook, but the talent and infrastructure are why companies actually stay.
Why Your Legal Structure Matters More Than You Think
Before you can access any of these benefits, you need to make a foundational structural choice. When setting up an Australian presence, you have two options: create a subsidiary or register as a branch office.
For anything involving serious R&D work, the subsidiary structure wins every time. Here’s why the distinction matters more than you might think.
An Australian subsidiary, formally called a proprietary limited company or “Pty Ltd”, exists as its own separate legal entity. Yes, your parent company owns 100% of the shares, but in the eyes of Australian law, it’s a distinct corporate person with its own liability shield.
A branch office is fundamentally different. It’s just your foreign parent company operating directly in Australia. There’s no separate entity at all.
Where this becomes critical for R&D operations
With a subsidiary structure, if something goes wrong in Australia, a supplier sues, an employee claims unfair dismissal, equipment fails and causes damage, the Australian entity deals with it. Your parent company’s exposure is ring-fenced to whatever you’ve invested in the subsidiary’s shares.
With a branch structure, there’s no ring-fence. Every debt, every obligation, every liability flows straight back to your parent company.
Think about the realities of R&D work. You’re investing millions in specialised equipment, hiring local staff under Australian employment law, creating intellectual property that could become the target of patent disputes, and signing multi-year leases. The liability exposure isn’t theoretical; it’s substantial and very real.
| Feature | Australian Subsidiary (Pty Ltd) | Branch Office |
|---|---|---|
| Legal Status | Separate Australian legal entity | Extension of your foreign parent |
| Liability | Limited to your investment | Unlimited—parent fully liable |
| Director Requirements | Need at least one Australian resident director | Must appoint a resident ‘local agent’ |
| Best For | Long-term R&D operations | Short-term projects or market testing |
The Five-Step Registration Roadmap
Setting up an Australian company is relatively straightforward. ASIC manages the process, and most of it can be completed online through the Australian Government’s Business Registration Service.
The five essential steps:
- Pick and reserve your company name – It must be unique, and it can be reserved for up to two months.
- Appoint officeholders – There needs to be at least one director who ordinarily resides in Australia.
- Get consents and addresses – You need written consent from all directors and shareholders, plus a physical Australian address.
- Submit your registration – Apply electronically and receive your Australian Company Number (ACN).
- Register for tax immediately – Get your Australian Business Number (ABN), Tax File Number (TFN), and register for GST and PAYG if needed.
One caveat: certain situations, like suppressing an officeholder’s address for security reasons, require a manual paper application rather than the streamlined online process.
The Australian Director Requirement (And How to Meet It)
Section 201A of the Corporations Act 2001 states clearly: “A proprietary company must have at least 1 director. That director must ordinarily reside in Australia.”
This isn’t a guideline, it’s law. That resident director has real legal responsibilities and can be held personally liable if the company fails to meet its statutory obligations.
The Catch-22: You’re an international company with no Australian presence yet. You can’t ask someone from your overseas team to take on this role; they don’t live in Australia. You can’t register without a resident director. And you’re understandably hesitant to give such a legally significant role to someone you don’t know well.
This exact problem has created a mature market for professional nominee director services. These provide a qualified, experienced, and insured Australian resident who acts as your nominee director for compliance purposes while you maintain control of operational decisions. It’s a practical solution that transforms a potential dealbreaker into a manageable operational cost.
All directors must also obtain a Director Identification Number (DIN) before appointment, a unique, lifetime identifier designed to promote corporate transparency.
When Foreign Investment Approval Becomes Your Biggest Hurdle
The Foreign Investment Review Board (FIRB) advises the Australian Treasurer on foreign investments. For 2025, if you’re from a Free Trade Agreement country (US, UK, Japan, Singapore), the general threshold is $1,464 million. Most R&D subsidiaries fall well below this.
But there’s a massive exception that catches many innovative companies off guard. The National Security Test changes everything.
If you’re acquiring 10% or more of a ‘national security business’, the monetary threshold is $0. Whether you’re investing $100,000 or $100 million, you need FIRB approval before you proceed.
The definition of ‘national security business’ includes entities that own or operate critical infrastructure (including data storage facilities), have contracts with defence or intelligence agencies, or store sensitive personal data of Australians.
Many tech companies (cybersecurity, AI, data analytics) and life sciences companies (handling health data) fall within this definition. Once classified as a national security business, every future funding round with a new foreign investor acquiring 10% or more requires FIRB approval, directly impacting your fundraising timeline.
The 43.5% Cash Refund Explained
The R&D Tax Incentive is the Australian Government’s primary mechanism for stimulating innovation. Unlike competitive grants, this is an entitlement program. If your activities and expenditure meet the criteria, you’re entitled to the benefit.
The program is jointly administered by the Department of Industry, Science and Resources (DISR), which assesses R&D activities, and the Australian Taxation Office (ATO), which assesses expenditure. For companies seeking to optimise their R&D financing strategy, understanding how this incentive works is crucial.
What You Need to Qualify
Three core requirements must all be satisfied:
First, you need to be an eligible entity, typically a company incorporated under Australian law.
Second, your activities need to qualify as eligible R&D. You must conduct at least one ‘core R&D activity’, an experimental activity where the outcome cannot be known in advance, conducted to generate new knowledge through systematic experimentation from hypothesis to evaluation.
Third, your expenditure must meet the threshold, at least $20,000 in eligible R&D expenditure within an income year.
Understanding the Financial Benefit
The value depends on your company’s aggregated turnover:
For companies with aggregated turnover less than $20 million, you receive a refundable tax offset equal to your corporate tax rate plus an 18.5% premium. With the current 25% small business tax rate, that’s a 43.5% refundable offset.
If your Australian subsidiary spends $1 million on eligible R&D, you’d receive $435,000 back. If your company has no tax liability, the ATO pays the full amount as direct cash.
For companies with an aggregated turnover of $20 million or more, you receive a non-refundable tax offset with tiered premiums of 8.5% or 16.5% depending on R&D intensity, which can only reduce tax payable.
| Aggregated Turnover | Offset Type | Real-World Benefit |
|---|---|---|
| Less than $20M | Refundable | 43.5% cash refund with 25% tax rate |
| $20M or more | Non-refundable | Reduces tax bill, worth 8.5-16.5 cents per dollar |
The difference between a cash refund and a non-refundable offset is massive for cash flow. This brings us to the biggest trap for foreign-owned subsidiaries.
The Four Fatal Mistakes That Kill R&D Tax Claims
The ATO is scrutinising foreign-owned subsidiaries, and getting your structure wrong means losing the entire benefit.
Mistake #1: The Global Turnover Calculation
Remember that $20 million threshold? Here’s the catch that surprises almost every international company.
The definition of ‘aggregated turnover’ is global. It includes your Australian subsidiary’s turnover, plus the turnover of your foreign parent company and its entire corporate group worldwide.
Here’s a realistic scenario: You’re a US software company with $50 million annual revenue. You set up a small Australian R&D subsidiary with zero revenue. Looking at the Australian entity alone, you’d assume eligibility for the 43.5% cash refund.
However, that’s wrong. Your parents’ $50 million gets included. Your subsidiary is immediately over the threshold, receiving only a non-refundable offset instead of cash refunds. The entire business case just evaporated.
What you must do: Calculate your global group turnover with an Australian tax adviser before you incorporate. This single calculation determines whether your Australian expansion is financially viable on the terms you think it is.
Mistake #2: The “Conducted For” Test and Economic Substance
Taxpayer Alert TA 2023/5 warns that the ATO is concerned about Australian subsidiaries of foreign companies claiming the R&D Tax Incentive for activities conducted for their foreign parent’s benefit rather than their own.
The ATO will examine “the economic or commercial substance of the arrangements, not only the legal form”. Having legally watertight contracts isn’t enough. They’ll look at who actually controls the R&D, who owns the results, and who bears the financial risk.
The three critical questions:
- Who Controls the R&D? Strategic decisions need to sit with the Australian entity, not be dictated by the parent.
- Who Owns the IP? If intercompany agreements automatically assign all IP to the foreign parent, it’s difficult to argue the benefit accrued to the Australian subsidiary.
- Who Bears Financial Risk? Non-recourse loans from the parent are a major red flag; they suggest the Australian entity isn’t genuinely at risk.
Your entire operational model needs to demonstrate genuine local substance through local decision-making, equity capitalisation rather than non-recourse debt, and retention of tangible economic interest in the IP developed.
H3: Mistake #3: IP Ownership Structures That Trigger ATO Scrutiny
IP rights are territorial; your foreign patent doesn’t protect you in Australia. But the strategic question of who owns the IP created by your Australian R&D team has enormous implications for R&D finance eligibility.
Model A: Australian Subsidiary Owns the IP
- Upside: Provides the strongest evidence that R&D was conducted for the Australian entity’s benefit, significantly de-risking your R&D Tax Incentive claim.
- Downside: IP value sits in Australia. Any royalty payments or asset sales face Australian tax, including withholding taxes on cross-border payments.
Model B: Foreign Parent Owns the IP
- Upside: Centralises all group IP for streamlined global management.
- Downside: This is a primary target of Taxpayer Alert TA 2023/5. If the Australian entity has limited ability to commercially exploit developed IP, the claim is at high risk.
The compromise: Many companies use a hybrid approach where the Australian subsidiary owns the IP but grants the parent an exclusive, royalty-bearing licence for global exploitation. This keeps ownership in Australia while giving the parent necessary commercial rights.
Mistake #4: Poor Record-Keeping That Fails ATO Audits
The ATO requires contemporaneous documentation to substantiate claims. If you can’t produce records that capture hypotheses, experiments, and evaluations as they happened, your claim can be disallowed even if you conducted legitimate R&D.
The solution: Implement documentation systems from the start, and build record-keeping into your project management workflow.
Beyond Setup: The Day-to-Day Realities of Governance and Compliance
Incorporation is the starting line, not the finish line. Running an Australian subsidiary of a foreign company carries significant, non-negotiable compliance obligations that begin on day one. Failing to manage these operational realities can undermine your legal standing and, critically, jeopardise your R&D Tax Incentive claims during an audit.
Beyond the major hurdles of FIRB and the Director ID, your ongoing governance framework must account for three key areas:
- Tax and Accounting: Your new entity must be registered for GST and PAYG (Pay As You Go) withholding for employees. You will be responsible for lodging regular Business Activity Statements (BAS) with the ATO (usually quarterly) and preparing an annual income tax return. These filings are separate from and in addition to your yearly R&D Tax Incentive application.
- Corporate Secretarial: ASIC (the corporate regulator) requires an annual company statement to be reviewed and a fee to be paid. You must maintain a register of members and formally document any changes to company details, such as a new registered office address or a change in directors. Your resident director is legally responsible for ensuring the company maintains proper financial records and does not trade while insolvent.
- Transfer Pricing: This is the most critical ongoing risk for an Australian subsidiary of a foreign company. Any transaction between your subsidiary and its overseas parent, such as management service fees, intercompany loans, or IP licensing agreements, is under intense ATO scrutiny. You must maintain contemporaneous documentation proving these transactions are priced at “arm’s length” (i.e., what two independent parties would agree to). This documentation is not optional; it is a core component of demonstrating the genuine economic substance that Taxpayer Alert TA 2023/5 demands.
These ongoing compliance tasks are not just administrative burdens. They are the evidence you will use to prove your subsidiary is a genuine, standalone entity operating for its own benefit, a cornerstone of a successful R&DTI claim.
Beyond the Tax Incentive: Other R&D Funding Sources
- Biomedical Translation Fund (BTF): A $500 million equity co-investment venture capital program for commercialising biomedical discoveries.
- Medical Research Future Fund (MRFF): A $24.5 billion long-term investment vehicle funding health and medical research through competitive grants.
- State Programs: Each state offers innovation grants. Advance Queensland, for example, includes co-funding for SMEs and matched funding for women-founded enterprises.
These grants are competitive and project-specific, unlike the entitlement-based R&D Tax Incentive, but provide valuable supplementary funding for companies seeking comprehensive R&D finance solutions.
Your Pre-Launch Checklist
Before incorporating or committing capital:
☐ Calculate global aggregated turnover to determine R&DTI eligibility tier
☐ Engage Australian legal and tax specialists with R&DTI expertise
☐ Assess FIRB national security implications
☐ Determine IP ownership strategy balancing R&DTI and global management
☐ Design intercompany agreements demonstrating genuine Australian substance
☐ Structure funding through equity rather than non-recourse debt
☐ Identify the resident director solution
☐ Plan R&D record-keeping systems
What Successful Companies Do Differently
Australia offers a compelling proposition: 43.5% cash refunds on eligible R&D, world-class talent, political stability, and bipartisan innovation support backed by $14.4 billion in annual government funding.
But accessing these benefits requires getting your structure right from day one. The decisions you make about corporate structure, IP ownership, intercompany agreements, and funding mechanisms directly determine whether you’ll receive substantial R&D Tax Incentive benefits or find them blocked during an ATO audit.
Companies that succeed understand the global turnover calculation before building financial models, structure subsidiaries to demonstrate genuine economic substance, maintain clear documentation, and engage specialist advisers who understand both international structures and Australian R&D incentives.
Companies that struggle treat incorporation as a simple administrative task, assume overseas structures can be replicated without modification, and discover structural problems after spending millions on R&D.
Making Your Australian R&D Expansion Work
The opportunity is substantial, but the regulatory framework is sophisticated, and the ATO is actively scrutinising foreign-owned subsidiaries. Invest the time and resources upfront to get your structure right. The return in preserved R&D Tax Incentive eligibility will far exceed the cost of proper planning.
Rocking Horse Group supports international companies establishing Australian subsidiaries for R&D operations by providing funding that works alongside the R&D Tax Incentive (R&DTI). We don’t replace or compete with the R&DTI. Instead, our funding complements it by giving you early access to the capital you expect to receive through your future R&DTI refund. This means your new Australian R&D entity can maintain strong cash flow, invest in local talent, and accelerate innovation from day one.
If you’re exploring the best way to structure your Australian R&D subsidiary, download our R&D Subsidiary Structuring Checklist or schedule a complimentary pre-assessment with our Australian expansion specialists. The opportunity is real—and with the right funding strategy in place, you can make the most of it from the start.